Preliminary results of the third phase of trials show that the Russian vaccine against coronavirus Sputnik V is 91.6% effective.
According to the authoritative scientific journal “The Lancet”, antibodies were developed in 98% of people, a cellular immune response was formed in 100% of volunteers.
The tests were carried out on the basis of 25 Moscow hospitals with the participation of almost 20 thousand people, including more than 2 thousand people over 60 years old. Three quarters of the volunteers received the real vaccine, the rest received a placebo.
The Lancet draws attention to the fact that vaccination did not lead to serious side effects. After vaccination, the volunteers only experienced cold symptoms, pain at the injection site and weakness.
The Sputnik V vaccine is similar to the AstraZeneca product. The only difference is that the Russian development is based on two different adenoviruses. This allows for a more stable and long-term immune response.“Political Action”. Foreign Ministry evaluates the arrival of diplomats in court with Navalny